Epidemiology and hospital resources use in the treatment of ulcerative colitis at gastroenterology units in Spain (EPICURE study)

Article Details

Authors
Ignacio Marín-Jiménez MD, PhD, Cristina Saro MD, Verónica Díaz PhD, Manuel Barreiro-de Acosta MD, PhD, María Gómez-García MD, PhD, Ana Gutiérrez Casbas PhD, on behalf of the working group of EPICURE study

Article Type
Original Research

DOI
10.7573/dic.212505

Related Articles

Article Page

Abstract

Background and aim: Nationwide epidemiological data on ulcerative colitis (UC) in Spain are lacking. The primary objective was to assess the epidemiology of UC at hospital gastroenterology units and the use of hospital resources (characteristics and facilities) for the management of UC in Spain.

Methods: A retrospective, multicenter, epidemiological, crosssectional study (EPICURE study) analyzed data from hospital registries and records from UC patients admitted and treated in 2011 at a representative selection of Spanish sites. The prevalence of UC in gastroenterology units was calculated as the total UC patients divided by the total inhabitants covered by those sites. Incidence was defined as the number of new UC cases during 2011 divided by the total inhabitants covered by those sites.

Results: In 2011, a total of 42,000 patients were attended for UC in gastroenterology units in Spain with a prevalence rate of 88.7 UC cases (95% CI: 69.6–106.0) per 100,000 inhabitants. The incidence rate was of 5.7 cases (95% CI: 1.2–10.8)/100,000 inhabitants. Six percent of patients being attended for UC were hospitalized in the 58 units analyzed in 2011. There were 1075 hospitalizations related to UC in total (approximately 14 per gastroenterology unit; median hospital stay length: 8 days). Six out of 1000 UC patients underwent colectomy in 2011. Near one third (32.7%) were emergency colectomies. Most hospitals had specific IBD units (87.9%) and colorectal surgeons (93.1%).

Conclusions: Our study provides the first national data on the prevalence and incidence of UC in gastroenterology units in Spain. Hospitalization and surgical burden associated with UC was low.

Keywords: colitis, incidence, patient care, prevalence, Spain, ulcerative epidemiology.

Citation: Marín-Jiménez I, Saro C, Díaz V, Barreiro-de Acosta M, Gómez- García M, Casbas AG, on behalf of the working group of EPICURE study. Epidemiology and hospital resources use in the treatment of ulcerative colitis at gastroenterology units in Spain (EPICURE study). Drugs in Context 2018; 7: 212505. DOI: 10.7573/dic.212505

Contributions: IM-J, CSG, MBD, MGG and AG carried out the study, and participated in its design and coordination and helped to draft the manuscript. VG participated in the design of the study and data analyses and drafted the manuscript. All authors read and approved the final manuscript. Other institutions and principal investigators who participated in the study are as follows: Victor Amo (H Carlos Haya, Málaga), Álvaro Hernández Martínez (H Torrecárdenas, Almería), Raquel Camargo Camero (H Virgen de la Victoria, Málaga), Juan Jesús Puente Gutiérrez (H Alto Guadalquivir, Jaén), Ana Mª Trapero (H de Jaén, Jaén), Rebeca Ruiz Morales (H de Cabra, Córdoba), María Dolores Retamero Orta (H Comarcal de la Axarquia, Málaga), María Rojas (H de Valme, Sevilla), Beatriz Benítez Rodríguez (H Juan Ramón Jiménez, Huelva), Alfredo Abraldes Bechiarelli (H Puerta del Mar, Cádiz), Sonia Gallego Montañés (H Miguel Servet, Zaragoza), Sabino Riestra Menéndez (H Central de Asturias, Oviedo), Daniel Ceballos Santos (H Dr Negrín, Gran Canaria), Samir Amine Salha (H Dr José Molina Orosa, La Palma), Montserrat Rivero (H de Valdecilla, Santander), Óscar Roncero García Escribano (H de Alcázar de San Juan, Ciudad Real), Jesús Barrio Andrés (H Rio Hortega, Valladolid), Fernando Muñoz (H de León, León), Beatriz Sicilia Aladrén (Complejo Asistencial Universitario de Burgos, Burgos), Eduard Cabré (Hospital Germans Trias i Pujol, Barcelona), Jose Miguel Boudet (H Arnau de Vilanova de Lleida), David Busquets Casals (H Josep Trueta de Girona), David Monfort Miquel (Consorcio Sanitario de Terrassa, Barcelona), Mercedes Navarro Llavat (H Sant Joan Despí Moisés Broggi, Barcelona), Xavier Calvet (H Parc Taulí, Barcelona), Sandra Torra Alsina (Parc Sanitari Sant Joan de Deu, Barcelona), Mª del Mar Alcalde Rubio (H Infanta Cristina, Badajoz), María Dolores Hernández Durán (H Virgen del Puerto; Cáceres), Ana Echarri Piudo (H Arquitecto Marcide; A Coruña), Luisa de Castro Parga (H Meixoeiro, Vigo), Rocío Ferreiro (Hospital Clínico Universitario de Santiago de Compostela), Carlos Taxonera Samso (H Clínico San Carlos, Madrid), Javier Pérez Gisbert (H La Princesa,Madrid), Elena Garrido Gómez (H Ramón y Cajal,Madrid), Isabel Vera Mendoza (H Puerta de Hierro,Madrid), Ángeles Masedo González (H 12 de Octubre,Madrid), Mª Dolores Martín Arranz (H La Paz,Madrid), Luis Menchen Viso (H Gregorio Marañón,Madrid), Daniel Martín Rodríguez (H Infanta Cristina, Madrid), Ramón Pajares Villarroya (H Infanta Sofía,Madrid), Emilio Torrella Cortés (H Morales Meseguer, Murcia), Teresa Martínez Giménez (H Rafael Méndez, Murcia), Patricia Romero Cara (H Santa Lucía, Murcia), Cristina Rodríguez Gutiérrez (H de Navarra, Pamplona), Carmen Muñoz Villafranca (H de Basurto, Vizcaya), Carmen Molina Álvarez (H Santiago Apóstol, Miranda de Ebro, Burgos), Silvia Estrada Oncins (H Txangorritxu, Guipuzcoa), Sam Khorrami Minaei (H Son Espases, Palma de Mallorca), José Mª Paredes Arquiola (H Dr Peset, Valencia), Maríam Aguas Peris (H La Fe, Valencia), Joaquín Hinojosa del Val (H de Manises, Valencia), Xavier Cortés (H de Sagunto, Valencia).

Disclosure and potential conflicts of interest: The design, study conduct and financial support for the clinical trial was provided by AbbVie. AbbVie participated in the interpretation of data, review and approval of the manuscript. Dr IM-J has served as a speaker, a consultant and advisory member for or has received research funding from MSD, Abbvie, Takeda, Janssen-Cilag, Ferring, Faes Farma, Shire Pharmaceuticals, Dr Falk Pharma, Chiesi, Gebro Pharma, Otsuka Pharmaceutical and Tillots. Dr CSG has served as a consultant for AbbVie, MSD, Ferring and Tillotts, and has received research funding from AbbVie, and speaker fees from AbbVie, MSD, Ferring and Tillotts. VD is an employee of AbbVie. Dr MBD has served as a speaker, a consultant and advisory member for, and has received research funding from MSD, Takeda, Khern, Abbvie, Hospira, Ferring, Falk, Faes Farma, Shire Pharmaceuticals and Chiesi. Dr MGG has served as a consultant for AbbVie and Centocor Ortho-Biotech, and speaker fees from Centocor Ortho-Biotech. Dr AG has served as a consultant for AbbVie, MSD, Hospira and has received research funding from AbbVie and MSD and speaker fees from Abbvie, MSD, Hospira, Ferring and Shire. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at: https://www.drugsincontext.com/wp-content/uploads/2018/02/dic.212505-COI.pdf

Acknowledgements: Editorial assistance was provided by Content Ed Net (Madrid, Spain).

Copyright: Copyright © 2018 Marín-Jiménez I, Saro C, Díaz V, Barreiro-de Acosta M, Gómez-García M, Casbas AG, on behalf of the working group of EPICURE study. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2018 Marín-Jiménez I, Saro C, Díaz V, Barreiro-de Acosta M, Gómez-García M, Casbas AG, on behalf of the working group of EPICURE study. https://doi.org/10.7573/dic.212505. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/epidemiology-and-hospital-resources-use-in-the-treatment-of-ulcerative-colitis-at-gastroenterology-units-in-spain-epicure-study

Correspondence: Ignacio Marín-Jiménez, Sección de Gastroenterología, Servicio de Aparato Digestivo, Hospital General Universitario Gregorio Marañón, C/ Doctor Esquerdo, 46, 28007 Madrid, Spain. drnachomarin@hotmail.com

Provenance: submitted; externally peer reviewed.

Submitted: 30 June 2017; Peer review comments to author: 20 July 2017; Revised manuscript received: 29 January 2018; Accepted: 3 February 2018; Publication date: 6 March 2018.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252772009.

For all manuscript and submissions enquiries, contact the Editorial office dic.editorial@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF